ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,918.25
      0.00%
      US Tech 100
      20,607.20
      -0.02%
      Dow Jones
      42,635.20
      0.00%
      Brent Oil
      79.255
      3.03%
      Bitcoin
      94,983.56
      2.78%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Verve Therapeutics Inc (VERV) Quote

      Verve Therapeutics Inc

      Verve Therapeutics Inc (VERV)

      Verbund Ag
      Verbund Ag
      Verbund Ag
      Verbund Ag
      6.01
      -0.41
      (-6.39%)
      Closed January 08 4:00PM
      Delayed by 15 minutes
      6.01
      0.00
      ( 0.00% )
      Pre Market: 6:26AM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      6.01
      Bid
      5.87
      Ask
      6.64
      Volume
      1
      0.00 Day's Range 0.00
      4.305 52 Week Range 19.34
      Market Cap
      508.83M
      Previous Close
      6.01
      Open
      -
      Last Trade
      1
      @
      6.01
      Last Trade Time
      06:26:46
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      1,511,131
      Shares Outstanding
      84,663,840
      Dividend Yield
      -
      PE Ratio
      -2.54
      Earnings Per Share (EPS)
      -2.36
      Revenue
      11.76M
      Net Profit
      -200.07M

      About Verve Therapeutics Inc

      Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.vervetx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was $6.01. Over the last year, Verve Therapeutics shares have traded in a share price range of $ 4.305 to $ 19.34.

      Verve Therapeutics currently has 84,663,840 shares outstanding. The market capitalization of Verve Therapeutics is $508.83 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -2.54.

      Ask ADVFN Intelligence (AI)

      VERV Latest News

      More News

      FeaturedCannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

      22 hours ago

      Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...

      January 08 2025
      GlobeNewswire Inc.

      Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December...

      January 03 2025
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 04 2024
      Edgar (US Regulatory)

      Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November...

      November 29 2024
      GlobeNewswire Inc.

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 08 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 05 2024
      Edgar (US Regulatory)

      Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

      Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the...

      November 05 2024
      GlobeNewswire Inc.

      Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October...

      November 01 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.12-1.957585644376.136.8655.99513561896.26355255CS
      4-0.09-1.475409836076.16.8654.8814748475.76579377CS
      120.549.872029250465.477.664.4415111315.88275257CS
      26-0.3-4.754358161656.317.964.30514233635.75304993CS
      52-7.88-56.731461483113.8919.344.30513615777.30032927CS
      156-25.69-81.041009463731.7434.305106987714.81073686CS
      260-23.99-79.966666666730784.30597302517.26556156CS

      VERV - Frequently Asked Questions (FAQ)

      What is the current Verve Therapeutics share price?
      The current share price of Verve Therapeutics is $ 6.01
      How many Verve Therapeutics shares are in issue?
      Verve Therapeutics has 84,663,840 shares in issue
      What is the market cap of Verve Therapeutics?
      The market capitalisation of Verve Therapeutics is USD 508.83M
      What is the 1 year trading range for Verve Therapeutics share price?
      Verve Therapeutics has traded in the range of $ 4.305 to $ 19.34 during the past year
      What is the PE ratio of Verve Therapeutics?
      The price to earnings ratio of Verve Therapeutics is -2.54
      What is the cash to sales ratio of Verve Therapeutics?
      The cash to sales ratio of Verve Therapeutics is 43.27
      What is the reporting currency for Verve Therapeutics?
      Verve Therapeutics reports financial results in USD
      What is the latest annual turnover for Verve Therapeutics?
      The latest annual turnover of Verve Therapeutics is USD 11.76M
      What is the latest annual profit for Verve Therapeutics?
      The latest annual profit of Verve Therapeutics is USD -200.07M
      What is the registered address of Verve Therapeutics?
      The registered address for Verve Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Verve Therapeutics website address?
      The website address for Verve Therapeutics is www.vervetx.com
      Which industry sector does Verve Therapeutics operate in?
      Verve Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      VMARVision Marine Technologies Inc
      $ 3.22
      (111.84%)
      		18.18M
      JSPRWJasper Therapeutics Inc
      $ 0.3074
      (98.32%)
      		2
      ZVSAZyVersa Therapeutics Inc
      $ 1.76
      (49.15%)
      		15.09M
      BAERBridger Aerospace Group Holdings Inc
      $ 4.13
      (48.03%)
      		8.28M
      IINNInspira Technologies Oxy B H N Ltd
      $ 1.43
      (43.00%)
      		4.63M
      IGMSIGM Biosciences Inc
      $ 1.84
      (-70.32%)
      		205.24k
      XXII22nd Century Group Inc
      $ 5.75
      (-29.01%)
      		5.91k
      SILOSilo Pharma Inc
      $ 1.30
      (-23.98%)
      		96.83k
      WMPNWilliam Penn Bancorporation
      $ 9.01
      (-22.99%)
      		1
      PCSCPerceptive Capital Solutions Corporation
      $ 8.00
      (-21.41%)
      		105
      VMARVision Marine Technologies Inc
      $ 3.22
      (111.84%)
      		18.18M
      ZVSAZyVersa Therapeutics Inc
      $ 1.76
      (49.15%)
      		15.09M
      GCTKGlucoTrack Inc
      $ 0.1251
      (-9.87%)
      		8.58M
      BAERBridger Aerospace Group Holdings Inc
      $ 4.13
      (48.03%)
      		8.28M
      RIMEAlgorhythm Holdings Inc
      $ 0.17
      (2.97%)
      		7.21M

      VERV Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 5 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 5 months ago
      VERV 10Q due AUGUST5
      👍️0
      Monksdream Monksdream 6 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 6 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      VERV more new lows up ahead
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 9 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 9 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 9 months ago
      VERV new 52 lo
      👍️0
      Firestorm22 Firestorm22 9 months ago
      uh oh
      👍️0
      Monksdream Monksdream 9 months ago
      VERV over $10
      👍️0
      fink fink 11 months ago
      Looking for an entry now
      👍️0
      Terpi Terpi 1 year ago
      Could see another nice move here is the 50 day holds into close.
      👍️0
      Monksdream Monksdream 1 year ago
      VERV morning rally
      👍️0
      TheFinalCD TheFinalCD 2 years ago
      https://cathiesark.com/
      👍️0
      crudeoil24 crudeoil24 3 years ago
      VERV IS A GREAT $$$$$ OPPORTUNITY.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
      👍️0

      Your Recent History

      NASDAQ
      VERV
      Verve Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads